Besides the announced diagnostic and prognostic values of the target panel for early CRC, our investigation provided evidence indicating CRC tumors may benefit of ACOT8/ACSL5/FASN/HMGBCS2/SCD1 axis activation for their structural and energetic demands without common lipidic toxicity such as overproducing endogenous ceramide by inhibition of SCD1 enzyme which previously reported in CRC cells [48]. This evidence concerns the gene FASN and colorectal carcinoma.